150 related articles for article (PubMed ID: 17379647)
1. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice.
Samadfam R; Xia Q; Goltzman D
Endocrinology; 2007 Jun; 148(6):2778-87. PubMed ID: 17379647
[TBL] [Abstract][Full Text] [Related]
2. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.
Samadfam R; Xia Q; Goltzman D
J Bone Miner Res; 2007 Jan; 22(1):55-63. PubMed ID: 17014384
[TBL] [Abstract][Full Text] [Related]
3. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
4. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
Pierroz DD; Bonnet N; Baldock PA; Ominsky MS; Stolina M; Kostenuik PJ; Ferrari SL
J Biol Chem; 2010 Sep; 285(36):28164-73. PubMed ID: 20558734
[TBL] [Abstract][Full Text] [Related]
5. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
Bauer DC; Garnero P; Bilezikian JP; Greenspan SL; Ensrud KE; Rosen CJ; Palermo L; Black DM
J Clin Endocrinol Metab; 2006 Apr; 91(4):1370-5. PubMed ID: 16449339
[TBL] [Abstract][Full Text] [Related]
6. Differential transcriptional effects of PTH and estrogen during anabolic bone formation.
von Stechow D; Zurakowski D; Pettit AR; Müller R; Gronowicz G; Chorev M; Otu H; Libermann T; Alexander JM
J Cell Biochem; 2004 Oct; 93(3):476-90. PubMed ID: 15372627
[TBL] [Abstract][Full Text] [Related]
7. μCT-based, in vivo dynamic bone histomorphometry allows 3D evaluation of the early responses of bone resorption and formation to PTH and alendronate combination therapy.
de Bakker CM; Altman AR; Tseng WJ; Tribble MB; Li C; Chandra A; Qin L; Liu XS
Bone; 2015 Apr; 73():198-207. PubMed ID: 25554598
[TBL] [Abstract][Full Text] [Related]
8. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats.
Ochi Y; Yamada H; Mori H; Kawada N; Tanaka M; Imagawa A; Ohmoto K; Kawabata K
J Bone Miner Metab; 2016 Jan; 34(1):33-40. PubMed ID: 25762435
[TBL] [Abstract][Full Text] [Related]
10. Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency.
White HD; Ahmad AM; Durham BH; Joshi AA; Fraser WD; Vora JP
J Clin Endocrinol Metab; 2011 Mar; 96(3):726-36. PubMed ID: 21252245
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of high dietary calcium and exogenous parathyroid hormone in promoting osteoblastic bone formation in mice.
Feng Y; Zhou M; Zhang Q; Liu H; Xu Y; Shu L; Zhang J; Miao D; Ren Y
Br J Nutr; 2015 Mar; 113(6):909-22. PubMed ID: 25744000
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
Szymczak J; Bohdanowicz-Pawlak A
Horm Metab Res; 2013 Sep; 45(10):759-64. PubMed ID: 23888411
[TBL] [Abstract][Full Text] [Related]
14. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
[TBL] [Abstract][Full Text] [Related]
15. Does bone resorption inhibition affect the anabolic response to parathyroid hormone?
Martin TJ
Trends Endocrinol Metab; 2004 Mar; 15(2):49-50. PubMed ID: 15080150
[TBL] [Abstract][Full Text] [Related]
16. Mice lacking bone sialoprotein (BSP) lose bone after ovariectomy and display skeletal site-specific response to intermittent PTH treatment.
Wade-Gueye NM; Boudiffa M; Laroche N; Vanden-Bossche A; Fournier C; Aubin JE; Vico L; Lafage-Proust MH; Malaval L
Endocrinology; 2010 Nov; 151(11):5103-13. PubMed ID: 20844009
[TBL] [Abstract][Full Text] [Related]
17. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
[TBL] [Abstract][Full Text] [Related]
18. Exogenous PTH and endogenous 1,25-dihydroxyvitamin D are complementary in inducing an anabolic effect on bone.
Samadfam R; Xia Q; Miao D; Hendy GN; Goltzman D
J Bone Miner Res; 2008 Aug; 23(8):1257-66. PubMed ID: 18348699
[TBL] [Abstract][Full Text] [Related]
19. Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice.
Machado do Reis L; Kessler CB; Adams DJ; Lorenzo J; Jorgetti V; Delany AM
Bone; 2008 Aug; 43(2):264-273. PubMed ID: 18499553
[TBL] [Abstract][Full Text] [Related]
20. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
